Search - tctmd.com

Displaying 61 - 80 of 118

Sort: Relevancy | Date

Presentation TCT 2017

DEFINE FLAIR/SWEDEHEART: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Thomas Engstroem

November 01, 2017

Presentation TCT 2017

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Presenter: Alfredo Trento, David J. Cohen

November 01, 2017

Presentation TCT 2017

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

Presenter: Bernard Prendergast, Brian K. Whisenant, David J. Cohen

November 01, 2017

News Conference News TCT 2017

VAMPIRE 3: Attenuated Plaque May Signal Benefit of Thrombus Removal in PCI

Shelley Wood

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Presenter: Mauricio G. Cohen, Simon R. Dixon, David Daniels

October 30, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Advertisement

DEFINE FLAIR/SWEDEHEART: Topline Findings and Practice Implications

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

VAMPIRE 3: Attenuated Plaque May Signal Benefit of Thrombus Removal in PCI

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Live From Denver: TCT 2017, Day Two

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Live From Denver: TCT 2017, Day One

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content